Vivek Subbiah: A study in the United States, Canada, & Germany using retrospective real-world databases

Vivek Subbiah, made the following post on Twitter:

“Hot off the press: Pleased to share our paper: Association between treatment and improvements in overall survival of patients with advanced/metastatic non–small cell lung cancer since 2011: A study in the United States, Canada, & Germany using retrospective real-world databases”

For details click here.
Source: Vivek Subbiah/Twitter

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.